Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

被引：50
作者：
Aisen, Paul S. [1 ]
Cummings, Jeffrey [2 ]
Schneider, Lon S. [3 ]
机构：
[1] Univ Calif San Diego, San Diego, CA 92093 USA
[2] Cleveland Clin, Cleveland, OH 44195 USA
[3] Univ So Calif, Los Angeles, CA 90007 USA
来源：
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE | 2012年 / 2卷 / 03期
关键词：
MILD COGNITIVE IMPAIRMENT; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHOLINESTERASE-INHIBITORS; MEMANTINE TREATMENT; GINKGO-BILOBA; VASCULAR DEMENTIA; CLINICAL-TRIALS; VITAMIN-E; PHASE-II;
D O I：
10.1101/cshperspect.a006395
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-D-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
引用
收藏
页数：21
相关论文
共 94 条
  • [1] A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
    Aisen, P. S.
    Saumier, D.
    Briand, R.
    Laurin, J.
    Gervais, F.
    Tremblay, P.
    Garceau, D.
    [J]. NEUROLOGY, 2006, 67 (10) : 1757 - 1763
  • [2] High-dose B vitamin supplementation and cognitive decline in Alzheimer disease - A randomized controlled trial
    Aisen, Paul S.
    Schneider, Lon S.
    Sano, Mary
    Diaz-Arrastia, Ramon
    van Dyck, Christopher H.
    Weiner, Myron F.
    Bottiglieri, Teodoro
    Jin, Shelia
    Stokes, Karen T.
    Thomas, Ronald G.
    Thal, Leon J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (15): : 1774 - 1783
  • [3] Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial
    Aisen, PS
    Schafer, KA
    Grundman, M
    Pfeiffer, E
    Sano, M
    Davis, KL
    Farlow, MR
    Jin, S
    Thomas, RG
    Thal, LJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21): : 2819 - 2826
  • [4] A randomized controlled trial of prednisone in Alzheimer's disease
    Aisen, PS
    Davis, KL
    Berg, JD
    Schafer, K
    Campbell, K
    Thomas, RG
    Weiner, MF
    Farlow, MR
    Sano, M
    Grundman, M
    Thal, LJ
    [J]. NEUROLOGY, 2000, 54 (03) : 588 - 593
  • [5] The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    Albert, Marilyn S.
    DeKosky, Steven T.
    Dickson, Dennis
    Dubois, Bruno
    Feldman, Howard H.
    Fox, Nick C.
    Gamst, Anthony
    Holtzman, David M.
    Jagust, William J.
    Petersen, Ronald C.
    Snyder, Peter J.
    Carrillo, Maria C.
    Thies, Bill
    Phelps, Creighton H.
    [J]. ALZHEIMERS & DEMENTIA, 2011, 7 (03) : 270 - 279
  • [6] Bachurin S, 2001, ANN NY ACAD SCI, V939, P425
  • [7] Bakchine S, 2008, J ALZHEIMERS DIS, V13, P97
  • [8] The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease
    Ballard, C
    Waite, J
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01):
  • [9] The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial
    Ballard, Clive
    Hanney, Maria Luisa
    Theodoulou, Megan
    Douglas, Simon
    McShane, Rupert
    Kossakowski, Katja
    Gill, Randeep
    Juszczak, Edmund
    Yu, Ly-Mee
    Jacoby, Robin
    [J]. LANCET NEUROLOGY, 2009, 8 (02) : 151 - 157
  • [10] Bentham P, 2004, LANCET, V363, P2105
12345678910